Dr. Weisman and His Patients Featured in Article About MCI
In neurology we learn the same lessons again and again: Time is brain.
Dr. Weisman and His Patients Featured in Article About MCI Read More »
In neurology we learn the same lessons again and again: Time is brain.
Dr. Weisman and His Patients Featured in Article About MCI Read More »
Lecanemab has not been as widely tested in Black patients.
ANA Featured in Washington Post Article About Leqembi Read More »
Almost anyone can take this quick test for Alzheimer’s without even going to the doctor. It’s a terrible idea.
Dr. Weisman Quoted in Article about Quest Rapid Alzheimer’s Test Read More »
Denial of coverage for lecanemab will have devastating consequences for millions of patients and families.
An Open Letter to Highmark and Independence Blue Cross Read More »
Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease.
FDA Converts Lecanemab to Traditional Approval Read More »
This recognition is a testament to Dr. Klein’s expertise and the high-quality headache care we deliver at Abington Neurological Associates.
Dr. Klein Receives American Headache Society Distinguished Service Award Read More »
On March 22, Weisman and his fellow advisers voted unanimously that the drug was ‘reasonably likely’ to prove beneficial, paving the way for the agency to approve it Tuesday.
Dr. Weisman Quoted in Philadelphia Inquirer Article about Tofersen Read More »
Tofersen, an injection treatment for a rare form of ALS, has been approved under the accelerated approval pathway.
FDA Gives Accelerated Approval to New ALS Treatment Read More »
The committee convened to discuss tofersen, an experimental injection for treatment of ALS.
Dr. Weisman participates in FDA Advisory Committee Read More »
Leqembi significantly reduces progression of memory loss in those with Alzheimer’s disease by about 30%.
ANA administers first lecanemab infusion in PA Read More »